IMPEDIMED LIMITED — Board/Management Information 2016

Aug 7, 2016

==> picture [226 x 43] intentionally omitted <==

August 8, 2016

ASX ANNOUNCEMENT

IMPEDIMED CHANGES TO BOARD OF DIRECTORS

Brisbane, Australia and Carlsbad, Calif. - ImpediMed Limited (ASX: IPD) a global provider of medical technology to measure, monitor and manage fluid status and body composition, today announced several changes to its Board of Directors.

Dr Michael Panaccio, a long-standing director, will retire from the Board of Directors, effective 8[th] August 2016.

In addition, Mr David Adams will stand down from his position as non-executive Director and member of the Nomination and Audit and Risk Management Committees, to take on an executive role with ImpediMed, as Senior Vice President of Ventures, Licensing and Corporate Development.

The company is also pleased to announce that Mr Gary Goetzke will join the ImpediMed Board as a non-executive Director, effective 8[th] August 2016.

Mr Goetzke has spent 15 years in senior management positions of three medical device companies where he lead efforts in pursuing global coverage and payment policy for a variety of medical device therapies in the areas of cardiology, neurology, urology, pelvic health, wound care, orthopedics, ENT, and sleep.

Dr Cherrell Hirst, Chair of ImpediMed said the Board and executive appointments bring another dimension of US medical device and financial experience to ImpediMed.

“As ImpediMed extends its commercial presence in the US and pursues new opportunities for its technology, we continue to evolve and add very high calibre talent to the Board and management teams. On behalf of the Board, I would like to thank Michael for his excellent contribution to ImpediMed over many years and I am very pleased to welcome Gary, who brings a wealth of experience in the medical device industry with considerable experience in US reimbursement.”

“I also congratulate David on his appointment to the executive team, and thank him for his valuable contribution to the Board over the past almost three years. In this new role, we will be able to make even better use of David’s skills and experience, as we continue on the journey of building a successful global organisation.”

Cherrell Hirst Chair

Richard Carreon Managing Director & CEO

For further information, contact: Richard Carreon, ImpediMed Managing Director & CEO Morten Vigeland, ImpediMed CFO T: +1 (760) 585-2100

Media Contacts:

In Australia:

Kyahn Williamson, Buchan T: +61 3 9866 4722 E: kwilliamson@buchanwe.com.au

In the US:

Paul Maccabee/Andy Pollen, Maccabee PR T: +1 612-337-0087

E: paul@maccabee.com; andy@maccabee.com

About ImpediMed

Founded and headquartered in Brisbane, Australia with U.S. offices in Carlsbad, Calif. and Bloomington, Minn., ImpediMed is the world leader in the development and distribution of medical devices employing bioimpedance spectroscopy (BIS) technologies for use in the noninvasive clinical assessment and monitoring of fluid status in patients. ImpediMed has the first medical device with FDA clearance in the U.S. to aid healthcare professionals to clinically assess secondary unilateral lymphoedema of the arm and leg in women and the leg in men. For additional information, visit www.impedimed.com.

==> picture [424 x 53] intentionally omitted <==